Chronic Allograft Nephropathy
11
0
0
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
9.1%
1 terminated out of 11 trials
87.5%
+1.0% vs benchmark
55%
6 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (11)
Validity of Strain Elastography for the Evaluation of Chronic Allograft Nephropathy
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy
Prevention of Kidney Transplant Rejection
Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants
Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients
Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function
Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy